SARTORIUS STEDIM, DEAR TO THE CORE (SELL; -29% DOWNSIDE)

23/02/21 -" Sartorius Stedim Biotech (Sell, France) ranks as a top-notch asset, with industry-leading return metrics (FY20 ROE of 26% vs 14% for AV peers). Since we noted its phenomenal run almost two years ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

23/02/21

Download

You may also be interested by these reports :

EXECUTIVE SUMMARY

Updates		Pension Risks
Target & Opinion		Governance & Management
Business & Trends		Graphics : Momentum
Money Making		Graphics : MACD & Volumes
Debt		Graphics : Sensitivities
Valuation		Sector: Performance
DCF		Sector: Key data
NAV/SOTP		Sector: Ratios & Valorisation
Worth knowing		Sector: Peers
Financials		Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking	NO
Trading in corporate shares	NO
Analyst ownership	NO
Advising of corporate (strategy, marketing, debt, etc)	NO
Research paid for by corporate	NO
Provision of corporate access paid for by corporate	NO
Link between and a banking entity	NO
Brokerage activity at AlphaValue	NO